The higher than expected incidence of IAPA at ICU admission (71% of IAPA cases) and the lower than expected incidence in the remaining MITT population precludes any definite conclusions on posaconazole as prophylacticum. Immediate diagnostic fungal assessment upon ICU admission combined with differentiated strategies are likely needed to manage IAPA in the ICU.